Searching for cancer tumors and identifying their precise behavior is a unique specialty talent honed by a select few from decades of experience and the right technology. World-recognized "tumor detective" Dr. Robert Bard is one of those specialized few- and the 3D/4D Doppler Ultrasound is his "weapon of choice" for capturing the earliest stage cancer from any depth below the skin.
TEST-DRIVING THE LATEST IMAGING INNOVATIONS
For over 30 years, Dr. Robert Bard has stood front and center in the race for advanced digital imaging advancement. Where MRI's, CT Scans and X-rays fall short in expectation and response, Dr. Bard's vision of the diagnostic future is one that's driven by the ultimate in "Trekian" Ultrasound technology (see TriCorder).
Recognized throughout the medical imaging development industry, Dr. Bard is one of the first to receive 'that' phone call from manufacturers when a "top-of-the-line" or "state-of-the-art" equipment is about to be launched to the test market. His name is trusted by engineers & designers worldwide for his priceless experience-based feedback as far as what the imaging community needs and what features these devices are supposed to bring to the table.
As the digital age of sub-dermal imaging technology continues to EVOLVE at a lightning fast pace, so does the demand for new capabilities that allows the diagnostician to "DO more and GET more out of the equipment". Where Dr. Bard's practice touts a non-invasive lung, prostate or breast cancer scan to deliver accurate screenings in record real-time (minutes), this has now become the next target STANDARD for health centers nationwide. It is this standard that is driving the revolution in the medical imaging market, where most European countries using ultrasound equipment as the primary standard for most musculo-skeletal, cardiovascular and transthoracic scans.
"it's not just about the device -- a lot of it has to do with WHO's reading it!", states Dr. Bard. "I've pushed last year's equipment to scan deeper and read more irregularities from tighter areas that their engineers did not design them to do- but in the end, identifying anomalies and cancer tumors correctly is always the name of the game."
Disclaimer & Copyright Notice: The materials provided on this website/web-based article are copyrighted and the intellectual property of the publishers/producers (The NY Cancer Resource Alliance/IntermediaWorx inc. and Bard Diagnostic Research & Educational Programs). It is provided publicly strictly for informational purposes within non-commercial use and not for purposes of resale, distribution, public display or performance. Unless otherwise indicated on this web based page, sharing, re-posting, re-publishing of this work is strictly prohibited without due permission from the publishers. Also, certain content may be licensed from third-parties. The licenses for some of this Content may contain additional terms. When such Content licenses contain additional terms, we will make these terms available to you on those pages (which his incorporated herein by reference).The publishers/producers of this site and its contents such as videos, graphics, text, and other materials published are not intended to be a substitute for professional medical advice, diagnosis, or treatment. For any questions you may have regarding a medical condition, please always seek the advice of your physician or a qualified health provider. Do not postpone or disregard any professional medical advice over something you may have seen or read on this website. If you think you may have a medical emergency, call your doctor or 9-1-1 immediately. This website does not support, endorse or recommend any specific products, tests, physicians, procedures, treatment opinions or other information that may be mentioned on this site. Referencing any content or information seen or published in this website or shared by other visitors of this website is solely at your own risk. The publishers/producers of this Internet web site reserves the right, at its sole discretion, to modify, disable access to, or discontinue, temporarily or permanently, all or any part of this Internet web site or any information contained thereon without liability or notice to you.
By: Robert L. Bard, MD A NEW RESEARCH STUDY IS UNDERWAY AT THE BARD CANCER CENTER IN NYC. Dr. Robert Bard and a local research team combine...
A SURGEON'S BEST PRE-OP PARTNER by: Dr. Robert Bard As health practitioners, we are so fortunate to be part of an era where inform...
Nesconset, NY (April 20, 2018) - Meet Long Island's own John Feal- an injured Ground Zero contractor turned national super-advocate an...
Note: The original publishing of this article is from AWARENESS FOR A CURE and PinkSmart News on July 31, 2018. ( LINK ) This article is a...